PubMed Health⌕ Search

Biomedical subjects

H G Dammann

Publications and source records attributed to H G Dammann.

At least 127 records · Page 7Linked to original sources
PubMed1985

[Single evening administration of etintidine in the human: effect on acid secretion and behavior of important hormones].

The potency and duration of action of a single dose of etintidine, ranitidine and cimetidine were compared in placebo-controlled studies. In addition, the effect of a single night-time dose of etintidine (600 mg) on gastric acid secretion and basal hormone levels was assessed before, during and after a 28-day treatment. Nocturnal gastric acidity (23.00-07.00) was inhibited from 41.04 +/- 5.0 mmol/l to 12.9 +/- 2.8 mmol/l by 300 mg etintidine, to 6.50 +/- 2.5 mmol/l by 600 mg etintidine and to 8.58 +/- 2.5 mmol/l by 800 mg cimetidine nocte. Etintidine and cimetidine did not reduce H+-concentrations during the following day. Pentagastrin-stimulated acid output was virtually not affected after 600 mg etintidine and 800 mg cimetidine as well. By contrast, stimulated acid secretion was still suppressed by about 50% following 300 mg ranitidine. Basal levels of testosterone, prolactin etc. remained unchanged by 28-day etintidine (600 mg dose at night) treatment. Clinical studies are needed to examine the place of the single dose of etintidine (600 mg) at night for the short-term treatment of duodenal ulcer.

Adult↗
PubMed1985

[I.v. famotidine versus i.v. ranitidine: intragastric pH behavior in surgical intensive care patients].

20 patients of a surgical intensive care unit were treated in a randomised double-blind fashion with i.v. famotidine 10 mg and i.v. ranitidine every 6-12 hours for maximally seven days. Both groups were comparable with respect to the grade of risk of stress-induced bleeding. With both H2-blockers (ranitidine and famotidine) the intragastric pH could be increased to 5.0 and more and kept constant at this level over the whole test period. The mean daily doses required were 22.3 mg for famotidine and 154.3 mg for ranitidine. Stress-induced bleeding as well as adverse reactions could not be observed in both treatment groups.

Adolescent↗
PubMed1985

[Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].

The aim of this study was to gain experience concerning efficacy and safety of famotidine, the new H2-receptor antagonist, for the maintenance of duodenal ulcer disease. 344 patients whose acute duodenal ulceration had recently been healed under famotidine or ranitidine were recruited for a year maintenance treatment with 20 mg bedtime dose of famotidine or placebo. 167 patients were treated with famotidine over 6 and 52 over 12 months. The corresponding numbers in the placebo control were 177 and 21. A life table method of analyses showed that the ulcer relapse rate was consistently and significantly (p less than 0.01) lower on famotidine than on placebo after 6 months (26% [43/167] versus 55% [98/177]). Of the 52 patients treated with 20 mg famotidine at night for further 6 months 7 (14%) developed an ulcer relapse. Of the 21 patients treated for further 6 months with placebo 5 (24%) showed an acute ulcer crater at endoscopy. Famotidine was well tolerated in the longterm therapy. The results confirm the efficacy and safety of famotidine in the prevention of duodenal ulcer relapse for at least 6 months.

Adult↗
PubMed1985

Intragastric acidity under 28-day omeprazole treatment.

The aim of our study was to investigate both the effect of 28-day treatment with omeprazole (30 mg orally once daily) and of repeated investigations on 24 h intragastric H+ activity. In double-blind randomized order, 10 healthy subjects received omeprazole and 5 placebo. 24 h acidity was determined before, during and after, treatment on days -8, -4, -1, 14 and 28, 32, 36, 42 and 70. A 90% reduction in the 24 h acid concentration was found after 14 and 28 days of treatment. Nocturnal H+ activity was decreased by 85%. No hyperacidity was observed after withdrawal of the drug. Control levels before, (between days -8 and -1) and after, therapy (between days 36 and 70), however, showed a significant increase in 24 h intragastric H+-activity. Summarizing, omeprazole 30 mg mane inhibits gastric acidity markedly both day and night. Repeated investigations at short intervals lead to a significant increase in intragastric acid concentration.

Adult↗
PubMed1985

Omeprazole heals duodenal, but not gastric ulcers more rapidly than ranitidine. Results of two German multicentre trials.

In two double-blind, randomized German multicentre trials the effects of omeprazole 20 mg mane and ranitidine 150 mg b.i.d. were compared for the first time in 334 outpatients with duodenal ulcer and 184 outpatients with gastric ulcer. In patients with duodenal ulcer endoscopically controlled healing rates after two weeks were 72% with omeprazole and 59% with ranitidine (p = 0.012); after 4 weeks 96 and 92%, resp. were healed (n.s.). In patients with gastric ulcer the healing rates after two, four, and eight weeks were 43, 81, and 95%, respectively, with omeprazole and 45, 80, and 90%, respectively, with ranitidine (n.s.). Smoking impaired healing in duodenal, but not in gastric ulcer. Symptom relief was comparable with both drugs. Serious side effects or clinically relevant changes in laboratory screening results were not detected. - Our results demonstrate for the first time that omeprazole 20 mg mane is superior to ranitidine 150 mg b.i.d. in the short-term treatment of duodenal, but not gastric ulcer.

Adolescent↗
PubMed1985

[Administration of ranitidine once in the evening for several weeks: effect on acidity and basal hormone levels in normal subjects].

The effects of ranitidine (300 mg at night) on gastric acid secretion as well as on basal hormone levels (testosterone, prolactin, dehydro-epiandrosterone etc.) were assessed in 9 healthy volunteers before, during and after a 28-day treatment. On day 29, i.e. 12 h after the last ranitidine dose, basal and stimulated acid secretion was only slightly reduced by some 14 and 12%, respectively. On day 35, gastric acid output had returned to pretreatment values. There were no signs of a rebound phenomenon. Basal levels of prolactin, testosterone, dehydroepiandrosterone etc. were unchanged by 28-day ranitidine treatment. Ranitidine 300 mg at night may, therefore, be used in the treatment of peptic ulcer disease without any negative effect on human gastric acid secretion and basal hormone levels.

Adult↗
PubMed1985

[Protective effect of two antacids in acute acetylsalicylic acid-induced injuries to the human gastric mucosa].

The present study deals with the protective effect of a pretreatment period with antacids (preparation A = gastropulgit) 50; 1 bag with suspension corresponding to 12.5 g contains: 1 g attapulgite, 1.8 g aluminium hydroxide-magnesium carbonate gel and 0.7 g sorbitol. Reference preparation B = commercial product; 1 bag with suspension corresponding to 10 ml contains: 600 mg magnesium hydroxide and 9 g aluminium hydroxide gel) on the acute acetylsalicylic acid (ASA)-induced lesions of gastric mucosa in man. 8 healthy volunteers received in a double-blind crossover design 1 or 2 bags of the antacids or placebo 15 min prior to 1500 mg p.o. of ASA. Endoscopy was performed 2 h later. In the placebo experiments ASA caused severe lesions in all volunteers (placebo values, study with preparation A: 2.9 +/- 0.1; study with preparation B: 2.8 +/- 0.2). Pretreatment with either one bag reduced the ASA-injuries to 2.2 +/- 0.3) (preparation A) and 2.1 +/- 0.3 (preparation B) (not significant compared with placebo). By contrast, a significant protection of human gastric mucosa against ASA could be achieved with 2 bags of preparation A, but not with 2 bags of preparation B (1.5 +/- 0.3, p less than 0.05; 1.9 +/- 0.3, p less than 0.05). The majority of the volunteers reported less discomfort evoked by ASA under the higher antacid doses.

Adult↗
PubMed1985

[The gastric tolerance of proglumetacin in man: comparison with indomethacin].

In healthy volunteers the effect of proglumetacin (Protaxon) on different functions of gastric and duodenal mucosa has been compared with that of indometacin in double-blind cross-over design. Pretreatment with 150 mg proglumetacin t.i.d. and 50 mg indometacin t.i.d. did not affect both human acid secretion as well as gastric microbleeding rate. Whereas treatment with 50 mg indometacin t.i.d. over 6 days induced gastric mucosal injury by about 2.4 +/- 0.25--as evaluated endoscopically--significantly lesser changes were seen following 150 mg proglumetacin t.i.d. (1.13 +/- 0.13) (p less than 0.001).

Adult↗
PubMed1984

[Antisecretory and mucosa-protecting drugs in the acute care of peptic ulcer. Review of action principles, healing rates and side effects of approved ulcer drugs and drugs under clinical trial].

Peptic ulcers can be treated successfully with antisecretory drugs and drugs which have a protective effect. Thanks to their good tolerance and a form of administration acceptable to patients, the H2-receptor antagonists have won a leading position amongst the other ulcer therapeutics. It remains to be seen whether the substituted benzimidazoles will develop into a serious competitor. Until now the clinical experiences with the prostaglandins in the treatment of ulcers are not very encouraging.

Acute Disease↗
PubMed1984

[Human acid secretion during daily administration of H2-blockers].

The potency and duration of a single dose of ranitidine and famotidine were compared in placebo-controlled studies. In addition, the effect of a single night-time dose of famotidine (40 mg) on gastric acid secretion and basal hormone levels was assessed before, during and after a 28-day treatment. Basal acid secretion was depressed by about 73% and 76% 12 hours after 300 mg ranitidine and 40 mg famotidine respectively. Pentagastrin-stimulated acid output was reduced by about 26% and 29%. 20 hours after both drugs, basal secretion was still inhibited by about 60%, whereas no effect on stimulated acid secretion could be detected. Nocturnal gastric acidity (23.00-07.00) was inhibited from 35.8 +/- 4.6 mmol/l to 1.8 +/- 0.5 mmol/l (94% inhibition) by 40 mg bedtime famotidine , and to 1.7 +/- 0.5 mmol/l (95% inhibition) by 300 mg ranitidine. Both drugs significantly reduced H+ concentrations during the following day. On day 29, i.e. 12 hours after the last famotidine dose, basal and stimulated acid secretion was reduced by some 50% and 26% respectively. On day 35, gastric acid output had returned to pretreatment values. Basal levels of prolactin, testosterone etc. were unchanged by 28-day famotidine treatment. Rantidine and famotidine may therefore be used as a single night-time dose in the acute treatment of peptic ulcer disease.

Adult↗
PubMed1984

[Ranitidine and cimetidine in the prevention of stress: ulcer hemorrhage a prospective comparative multicenter study].

In a multicentre single-blind study, ranitidine was compared to cimetidine as prophylactic treatment against stress-induced upper gastrointestinal bleeding in seriously ill patients in the intensive care unit (ICU). 380 patients entered the study. 192 patients were treated with ranitidine 50 mg q.i.d. as i.v. bolus followed by 150 mg orally twice daily. 188 patients received cimetidine 400 mg q.i.d. intravenously and 1,000 mg daily orally in divided doses. Five patients in the ranitidine group (2.6%) and 12 in the cimetidine group (6.4%) developed gastrointestinal bleeding definitely or possibly due to stress lesions. This difference was not significant. The incidence of stress erosions or ulcerations developing during the study was 11.8% for the ranitidine group and 18.3% for the cimetidine group (non-significant difference). Adverse events in the ranitidine group were nausea, tachycardia or vomiting in 4 patients. 5 cimetidine-treated patients developed cholestasis, and 5 additional central nervous system problems. The high degree of efficacy of both drugs compared very favourably with the high incidence of stress ulceration and hemorrhage in similar untreated populations.

Adolescent↗